Table 1 Experimental groups.*
Groups | Infection (P. aeruginosa) | Intervention | n |
|---|---|---|---|
Control | None | Â | 3 |
Co-instillation | Antibodies were premixed with PA103 | ||
   Control IgG | PA103 (5 × 107 CFU), IT | Control IgG (IgG2b), 4 mg/ml IT | 3 |
   Rab anti-PcrV | PA103 (5 × 107 CFU), IT | Polyclonal anti-PcrV IgG, 4 mg/ml IT | 3 |
   Mab166 | PA103 (5 × 107 CFU), IT | Monoclonal Mab166, 4 mg/ml IT | 3 |
Therapeutic | Antibodies were intratracehally instilled 1 h after the instillation of PA103 | ||
   w/o IgG | PA103 (5 × 107 CFU), IT | Phosphate-buffered saline | 5 |
   Rab anti-PcrV | PA103 (5 × 107 CFU), IT | Polyclonal anti-PcrV IgG, 4 mg/ml IT | 3 |
   Mab166 | PA103 (5 × 107 CFU), IT | Monoclonal Mab166, 4 mg/ml IT | 5 |
   Mab166 Fab | PA103 (5 × 107 CFU), IT | Fab fragments of Mab166, 4 mg/ml IT | 3 |